SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

SG Americas Securities LLC boosted its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) by 30.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,874 shares of the biopharmaceutical company’s stock after acquiring an additional 10,511 shares during the quarter. SG Americas Securities LLC’s holdings in Fate Therapeutics were worth $74,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in FATE. Castleview Partners LLC bought a new position in shares of Fate Therapeutics during the 3rd quarter valued at about $73,000. Intech Investment Management LLC bought a new position in shares of Fate Therapeutics during the 3rd quarter valued at about $108,000. Exchange Traded Concepts LLC increased its position in shares of Fate Therapeutics by 40.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 42,289 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 12,230 shares during the last quarter. Privium Fund Management B.V. bought a new position in shares of Fate Therapeutics during the 3rd quarter valued at about $175,000. Finally, Walleye Capital LLC increased its position in shares of Fate Therapeutics by 263.5% during the 3rd quarter. Walleye Capital LLC now owns 67,609 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 49,009 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on FATE shares. Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. Wedbush reiterated a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.75.

Fate Therapeutics Stock Performance

NASDAQ FATE opened at $1.27 on Friday. Fate Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $8.83. The stock has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $2.69. The stock has a market cap of $144.64 million, a P/E ratio of -0.77 and a beta of 2.02.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.02. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The business had revenue of $3.07 million during the quarter, compared to analysts’ expectations of $0.88 million. Sell-side analysts predict that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Redmile Group, Llc bought 397,964 shares of the stock in a transaction dated Friday, December 20th. The stock was bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the purchase, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. This trade represents a 3.19 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.00% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.